Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock
Authors:
- Patrick M. HonorePHPatrick M. Honore
- Jean JamezJJJean Jamez
- Michel WauthierMWMichel Wauthier
- Patrice A. LeePLPatrice A. Lee
- Thierry DugernierTDThierry Dugernier
- Bruno PirenneBPBruno Pirenne
- Genevieve HaniqueGHGenevieve Hanique
- James R. MatsonJMJames R. Matson
- 1 November 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 28 (11) , 3581-3587
Abstract
To evaluate the effects of short-term, high-volume hemofiltration (STHVH) on hemodynamic and metabolic status and 28-day survival in patients with refractory septic shock. Prospective, interventional. Intensive care unit (ICU), tertiary institution. Twenty patients with intractable cardiocirculatory failure complicating septic shock, who had failed to respond to conventional therapy. STHVH, followed by conventional continuous venovenous hemofiltration. STHVH consisted of a 4-hr period during which 35 L of ultrafiltrate is removed and neutral fluid balance is maintained. Subsequent conventional continuous venovenous hemofiltration continued for at least 4 days. Cardiac index, systemic vascular resistance, pulmonary vascular resistance, oxygen delivery, mixed venous oxygen saturation, arterial pH, and lactate were measured serially. Fluid and inotropic support were managed by protocol. Therapeutic endpoints were as follows during STHVH: a) by 2 hrs, a ≥50% increase in cardiac index; b) by 2 hrs, a ≥25% increase in mixed venous saturation; c) by 4 hrs, an increase in arterial pH to >7.3; d) by 4 hrs, a ≥50% reduction in epinephrine dose. Patients who attained all four goals (11 of 20) were considered hemodynamic “responders”; patients who did not (9 of 20) were considered hemodynamic “nonresponders.” There were no differences in baseline hemodynamic, metabolic, and Acute Physiology and Chronic Health Evaluation and Simplified Acute Physiology Scores between responders and nonresponders. Survival to 28 days was better among responders (9 of 11 patients) than among nonresponders (0 of 9). Factors associated with survival were hemodynamic-metabolic response status, time interval from ICU admission to initiation of STHVH, and body weight. These data suggest that STHVH may be of major therapeutic value in the treatment of intractable cardiocirculatory failure complicating septic shock. Early initiation of therapy and adequate dose may improve hemodynamic and metabolic responses and 28-day survival.Keywords
This publication has 37 references indexed in Scilit:
- Viral HepatitisBlood Purification, 1997
- Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of PathogenesisAnnals of Internal Medicine, 1994
- Pathogenetic Mechanisms of Septic ShockNew England Journal of Medicine, 1993
- Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patientsCritical Care Medicine, 1993
- High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pigIntensive Care Medicine, 1992
- The Pathogenesis of SepsisAnnals of Internal Medicine, 1991
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- Hemofiltration Reverses Left Ventricular Dysfunction during Sepsis in DogsAnesthesiology, 1990
- Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic ShockThe Journal of Infectious Diseases, 1990
- Use of survivorsʼ cardiorespiratory values as therapeutic goals in septic shockCritical Care Medicine, 1989